Discussion | In this study of 56 678 patients with confirmed inhospital cardiac arrest, we identified several key limitations of using administrative data for cardiac arrest research. Most studies have used a diagnosis or procedure code alone to identify cases of in-hospital cardiac arrest. However, we found that most confirmed cases in a national registry would not be captured using either administrative data strategy. Furthermore, survival rates using administrative data to identify cases from the same reference population varied markedly and were 52% higher (28.4% vs 18.7%) when using diagnosis codes alone to identify in-hospital cardiac arrest. Finally, there was large hospital variation in documenting diagnosis or procedure codes for patients with in-hospital cardiac arrest, which would have consequences for using administrative data to examine hospital-level variation in cardiac arrest incidence or survival, or for conducting single-center studies to validate this administrative approach. Our study highlights the collective challenges of using administrative billing data to conduct research on in-hospital cardiac arrest.
Our study was limited in that it did not evaluate the positive predictive value of cardiac arrest cases identified using administrative codes, or assess whether GWTG-Resuscitation captures all cardiac arrest cases in hospitals. Deidentification of data within GWTG-Resuscitation Medicare files precluded such analyses, but these additional issues present important areas of research for future studies.
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Postmarketing Adverse Events Related to the CardioMEMS HF System
The CardioMEMS HF System (Abbott), a wireless pulmonary artery (PA) sensor, was demonstrated to safely reduce heart failure (HF) hospitalizations in the randomized, singleblinded study of 550 patients, CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Class III Heart Failure Patients (CHAMPION product class ("system, hemodynamic, implant"), model number ("CM1000," "CM1010," "CM2000," and "CM3000"), brand name ("CardioMEMS" and "HF Sensor Delivery System"), and product code ("MOM," a unique FDA designation linked to the CardioMEMS HF System device). Analyses began in June 2017. An estimate of total device implants in the United States was obtained by sequential review of investor reports and press releases, 6 corroborated by a direct source from Abbott. Although this surveillance system cannot be used to establish definitive event rates, we provide estimates of device-, system-, or procedure-related adverse event rates. All MAUDE reports were publicly available with deidentified patient information. Thus, this study was exempt from institutional review board approval.
Results | During the first 3 years after FDA approval, there were more than 5500 total CardioMEMS HF System implants in the United States. Of these approximately 5500 implants, we identified 155 reports (2.8%) describing 177 unique adverse events during this reporting interval. The median time between the date of event and the date the FDA received a report was 42 days (interquartile range, 13-196 days), with 36 reports completed within 1 week of the event. Of 155 reports, 147 were mandatorily reported by the manufacturer/user facility (94.8%).
Overall adverse events accrued gradually during this time, but reports of PA injury/hemoptysis and deaths were clustered early after device introduction and appeared to stabilize over time ( Figure) . Of approximately 5500 implants, there were 28 reports of PA injury/hemoptysis (0.5%), which included 14 intensive care unit stays, 7 intubations, and 6 deaths. Eighteen technical challenges with implantation were reported, of which 14 were aborted. Sensor failure, malfunction, or migration occurred in 46 cases, of which 35 required recalibrations, 13 re- The treating physicians indicated that death was unlikely to be related to device or procedure (n = 5)
One patient was a clinical study participant
Unknown cause of death with limited event details or physician corroborating information (n = 4) NA Unrelated (n = 3)
Postimplantation renal failure and aspiration pneumonia occurred; the patient transitioned to comfort-oriented care and died
Severe PAD requiring procedure around time of implant The patient was readmitted after device implantation to another hospital with fevers and died of sepsis/infection NA The patient felt unwell with productive cough but refused to seek medical attention; the patient subsequently experienced cardiac arrest NA Abbreviations: HF, heart failure; NA, not available; PA, pulmonary artery; PAD, peripheral artery disease; PEA, pulseless electrical activity. Of approximately 5500 CardioMEMS HF System implants, 155 cumulative adverse events (2.8%), 28 PA injury or hemoptysis (0.5%), and 22 deaths (0.4%) were reported in the MAUDE database related to the CardioMEMS HF System since US Food and Drug Administration (FDA) approval. The absolute risks represent crude estimates of adverse event rates during the reporting interval. MAUDE indicates Manufacturer and User Facility Device Experience; PA, pulmonary artery; Q, quarter.
Letters implantations, and 11 hospitalizations (for reintervention, HF, or over-diuresis). Five sensors could not be used despite recalibration. Access site-related bleeding/infection (n = 15) and pulmonary embolism/device thrombosis (n = 5) were also reported. There were 22 total deaths (approximately 0.4%) (6 after PA injury/hemoptysis, 4 HF-related, and 12 unknown or likely unrelated) included in MAUDE reports (Table) . Limited details regarding patient histories were available, and no autopsies were reported.
Discussion | In the CHAMPION trial, 1 there were 15 adjudicated serious adverse events (2.6%) with 575 implant attempts, including 1 case of PA injury and 2 deaths. These postmarketing surveillance data provide an early look at the real-world safety profile of this device in less selected, higher-risk patients, demonstrating comparable estimated overall adverse event rates with the CHAMPION trial. However, these data bring greater attention to infrequent but potentially consequential risks of PA injury and need for reintervention or device recalibration. Similar to other interventional therapies, a learning curve may exist for the most serious observed complications (PA injury/hemoptysis and death). Careful candidate selection (patients well represented in the CHAMPION trial and included in the FDA label), greater operator training, and technological refinement (focused on minimizing risk of downstream sensor failure or need for recalibration) may improve device safety and durability. The FDA relies on several mechanisms to assess the safety of regulated devices after approval and market release. The Manufacturer and User Facility Device Experience database, being only 1 such surveillance system, is subject to certain limitations (incomplete patient profiling; underreporting, delayed reporting, or selective reporting; and lack of quality control or event adjudication). Given these shortcomings, these safety signals will need to be contextualized alongside other, parallel postmarketing surveillance efforts (ClinicalTrials.gov Identifier: NCT02279888) and potentially tracked in a dedicated CardioMEMS HF System registry.
Early detection of safety signals and general oversight of medical devices are challenging. The FDA receives more than 1 million device-related reports annually but has limited resources, clinical reviewers, and knowledge of total device use (the "denominator") to understand their clinical significance. Future partnerships between regulators, industry sponsors, and academia may help better triage available resources toward improving patient selection, operator experience, or device technology to optimize device use in clinical practice.
